Impact of phosphate binders on quality of life in dialysis patients: Results from the prospective Dutch nOcturnal and hoME dialysis Study To Improve Clinical Outcomes study. Issue 10 (19th September 2022)

• Record Type: Journal Article
• Authors: Colombijn, Julia M. T.; Vonk, Sanne; Cornelis, Tom; Boorsma, Siska; Krekels, Marielle M. E.; Abrahams, Alferso C.; van Jaarsveld, Brigit C.
• Is Part Of: Nephrology. Volume 27:Issue 10(2022)
• Page Start: 834
• Page End: 844
• Publication Date: 2022-09-19
• Subjects: dialysis -- phosphate binders -- phosphate binding agents -- polypharmacy -- quality of life; Nephrology -- Periodicals; Kidneys -- Diseases -- Periodicals; Nephrologists -- Periodicals; 616.61; 616.61
• DOI: 10.1111/nep.14088
• Languages: English
• ISSNs: 1320-5358

Abstract

Abstract: Background: Phosphate binders cause high pill burden for dialysis patients, complicate medication regimens, and have unpleasant taste and large size which may affect patients' quality of life. This study explores the association between phosphate binder pill burden and health‐related quality of life (HRQoL) in dialysis patients. Methods: We conducted a cross‐sectional multi‐centre cohort study in 21 Dutch dialysis centres. Phosphate binder pill burden was extracted from electronic patient records. Primary outcome was HRQoL measured with the Short Form 12 physical and mental component summary scores (PCS and MCS). Secondary endpoints were severity of gastro‐intestinal symptoms, itching, dry mouth, and mental health symptoms, measured with the Dialysis Symptom Index. Results: Of 388 included patients, aged 62 ± 16 years, 77% underwent haemodialysis. PCS scores were comparable for patients with and without phosphate binders. Patients using 1–3 pills reported lower scores for decreased appetite ( β −0.5; 95%CI −0.9 to −0.2), implying better appetite, than patients without phosphate binders. Patients using 4–6 pills also reported lower scores for decreased appetite ( β −0.5; 95%CI −0.8 to −0.1) and for itching ( β −0.5; 95%CI −0.9 to −0.1). Patients using >6 pills reported lower MCS ( β −2.9; 95%CI −6.2–0.4) and higher scores for feeling nervous ( β 0.6; 95%CI 0.1–1.1) and feeling sad ( β 0.4; 95%CI 0.0–0.9). Conclusion: Phosphate binder pill burden is not associated with physical quality of life. A higher pill burden is associated with better appetite and less itching. Patients using >6 pills per day report lower mental quality of life and felt nervous and sad more often. Summary at a glance: This cross‐sectional cohort study assessed the impact of phosphate binders on quality of life in dialysis patients. A higher phosphate binder pill burden was associated with worse mental quality of life, more severe feelings of nervousness and sadness, a better appetite, and less severe feelings of itching but not with physical quality of life.